07:00 , May 18, 2015 |  BC Week In Review  |  Clinical News

Dalazatide: Phase Ib data

Top-line data from the double-blind, Canadian Phase Ib 186-03 trial in 24 patients with active plaque psoriasis showed that twice-weekly 30 and 60 ug doses of subcutaneous dalazatide for 4 weeks were well tolerated. At...
07:00 , May 11, 2015 |  BioCentury  |  Product Development

Check your effectors

Phase Ib data reported last week for Kineta Inc.'s dalazatide gave the first clinical evidence that targeting Kv1.3 channels may quell an active autoimmune response by halting activation of effector memory T cells while avoiding...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Clinical News

Airmid, Kineta preclinical data

In a rat model of anterior uveitis, topical ShK-186 reduced disease severity and inflammatory cell infiltration. Data were presented at the Ocular Diseases Drug Discovery meeting in San Diego. Kineta has exclusive, worldwide rights to...
08:00 , Feb 2, 2015 |  BC Week In Review  |  Clinical News

ShK-186: Phase Ib complete enrollment

Kineta completed enrollment in a double-blind, placebo-controlled, Canadian Phase Ib trial evaluating biweekly subcutaneous ShK-186 for 4 weeks. Kineta licensed the compound from Airmid in 2009 (see BioCentury, July 13, 2009). Airmid Inc., Redwood City,...
07:00 , Oct 20, 2014 |  BC Week In Review  |  Clinical News

ShK-186: Phase Ib started

Kineta began a double-blind, placebo-controlled, Canadian Phase Ib trial to evaluate subcutaneous ShK-186 biweekly for 4 weeks in 24 patients. Kineta licensed the compound from Airmid in 2009 (see BioCentury, July 13, 2009). Airmid Inc.,...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Company News

Chimera Biotec, Kineta, KPI Therapeutics, Life Chemicals, Medical Marketing Economics, MPI Research, Seattle Children's Research Institute autoimmune news

Kineta and the CROs Chimera Biotec, Life Chemicals, Medical Marketing and MPI Research launched newco KPI Therapeutics to accelerate the development of early to mid-stage therapies from industry partners. KPI Therapeutics will jointly develop selected...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Company News

Kineta, RLB Holdings deal

Kineta and investment fund RLB formed JV Kineta RLB LLC to develop Kineta compounds, with an initial focus on autoimmune diseases. The partners provided undisclosed funding to the JV and are equal partners, according to...
07:00 , Apr 17, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Asthma Potassium channel Kv1.3 (KCNA3) Rat studies suggest KCNA3 antagonists could be useful for treating asthma. In...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

ShK-186: Phase Ib started

Kineta began a 2-part, U.S. Phase Ib trial of ShK-186. In the initial dose-escalation part, healthy volunteers will receive 1 of 4 doses of ShK-186 in a 28-day cycle until the maximum tolerated dose (MTD)...
07:00 , Jun 6, 2013 |  BC Innovations  |  Targets & Mechanisms

Watching obesity on a new channel

Researchers at the University of California, Irvine, have found a potassium channel Kv1.3 inhibitor that may help treat obesity-related diseases.1 The team had previously licensed one inhibitor, ShK-186, to Kineta Inc. for autoimmune indications-the biotech...